4/A: OptimizeRx Officer Amends Stock Transaction Filing

OptimizeRx's Chief Finance & Strategy Officer, Edward Stelmakh, filed an amended Form 4 to correct the transaction code for shares withheld for tax obligations.

Summary

• Edward Stelmakh, Chief Finance & Strategy Officer of OptimizeRx Corp (OPRX), filed an amended Form 4 (Form 4/A) to correct a previously reported transaction.
• The amendment clarifies that the disposition of 1,388 shares of common stock, originally reported with transaction code 'S' (sale), should have been reported with transaction code 'F' (shares withheld for tax obligations).
• These 1,388 shares were withheld by OptimizeRx to satisfy Mr. Stelmakh's tax withholding obligations related to the vesting of restricted stock units (RSUs).
• On December 19, 2025, 5,237 restricted stock units converted into common stock on a one-for-one basis.
• Following these transactions, Mr. Stelmakh beneficially owns 126,830 shares of OptimizeRx common stock.

Sentiment

Score: 5

Explanation: The filing is a routine amendment to correct a transaction code for insider stock activity, which is neutral in sentiment.

Future Outlook

The filing does not provide any forward-looking statements or guidance beyond the vesting schedule of restricted stock units.

Industry Context

This filing is a routine amendment to an insider transaction report and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a correction of an insider transaction, not a new event. It ensures accurate public record of executive compensation and holdings.

Next Steps

• Remaining restricted stock units will continue to vest in equal annual installments as per the grant terms.

Key Dates

Keywords

OptimizeRx, OPRX, SEC Form 4/A, Insider Transaction, Stock Filing, Restricted Stock Units, Tax Withholding, Edward Stelmakh, Corporate Governance